Viridium Reports Fiscal 2018 Third Quarter Results

October 24, 2018 8:10 PM

VANCOUVER, BC / ACCESSWIRE / October 24, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSX-V: VIR) (OTCPink: VIRFF) is pleased to announce its financial results for the third quarter of fiscal year 2018. The Company’s third quarter filings, including quarterly financial statements and "Management Discussion & Analysis" are now available on SEDAR (www.sedar.com). "Our third quarter was a strong push for us ahead of...

Read more

Dyadic to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

October 24, 2018 4:30 PM

JUPITER, FL / ACCESSWIRE / October 24, 2018 / Dyadic International, Inc. (''Dyadic'') (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will report its financial results for the quarter ended September 30, 2018 after the market...

Read more

Vitro BioPharma Engages Senior Director of Sales and Marketing

October 23, 2018 1:40 PM

GOLDEN, CO / ACCESSWIRE / October 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, today announced the engagement of a senior Sales and Marketing Director. The company has engaged Keith V. Burge to be its full time Director of Sale and Marketing. Mr. Burge has a B.S. in biology and has extensive experience in building sales channels and providing market branding for new products going to market. He has an entrepreneurial...

Read more

Molecular Loop Acquires MIP-Based DNA Targeting Technology

October 16, 2018 3:05 PM

Startup introduces streamlined, robust workflow for NGS sample preparation and analysis BOSTON, MA / ACCESSWIRE / October 16, 2018 / Molecular Loop Biosolutions LLC, a company specializing in advanced sample preparation solutions and data analysis for next-generation DNA sequencing, is pleased to announce the acquisition of Good Start Genetics' molecular inversion probe-based DNA targeting and analysis technology from Invitae Corporation. The...

Read more

Experion Receives License to Sell Starter Material

October 16, 2018 1:35 PM

VANCOUVER, BC / ACCESSWIRE / October 16, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSXV: VIR) (OTC PINK: VIRFF) is pleased to announce that its wholly owned subsidiary, Experion Biotechnologies Inc. ("Experion"), has received an amended license from Health Canada allowing for the sale of cannabis starter material, including cannabis seeds and live plants. This license permits Experion to distribute starter material to...

Read more

Mymetics Starts Research Collaboration Project in Cancer Immunotherapy with eTheRNA

October 16, 2018 2:00 AM

EPALINGES, SWITZERLAND / ACCESSWIRE / October 16, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines, announced today that Mymetics BV, the Dutch subsidiary of Mymetics Corporation, has entered into a research collaboration project with eTheRNA immunotherapy NV, a clinical stage biotech company developing novel mRNA cancer immunotherapies. The objective of the project is to...

Read more

Molecular Partners Invites Investors to Participate in its 2018 R&D Day

October 15, 2018 11:30 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 15, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics to treat serious diseases, is hosting its 2nd R&D update on "Building Tomorrow's Breakthroughs." When: Thursday, December 6, 2018 Check-In & Lunch 11:30am - 12:00pm ET Presentations and Q&A 12:00pm - 2:30pm ET Where: The Yale Club 50...

Read more

Viridium Pacific Group Announces C$16 Million Private Placement Financing

October 14, 2018 4:00 PM

VANCOUVER, BC / ACCESSWIRE / October 14, 2018 / Viridium Pacific Group Ltd. ("Viridium" or the "Company") (TSX-V: VIR) (OTC PINK: VIRFF) is proposing a common equity financing by way of a private placement of 17,582,418 units (the "Units") at a price of $0.91 per Unit (the "Offering Price") to raise aggregate gross proceeds to the Company of $16,000,000 Canadian dollars (the "Offering"). Under the terms of the financing, each Unit is comprised...

Read more

Sandesara Promoted Sterling Biotech Continues Advancing Loan Settlement Talks

October 11, 2018 4:30 PM

MUMBAI, INDIA / ACCESSWIRE / October 11, 2018 / The representatives of Sterling Biotech are progressing discussions with the Committee of Creditors (CoC) to settle outstanding loans. Beginning June 11, 2018, the company was admitted for insolvency proceedings within the Corporate Insolvency Resolution Process (CIRP). The CoC'S legal representative states that funds have been deposited into an escrow account intended for settling dues following...

Read more

New Mymetics Data Regarding Cold Chain Independent Virosome Based Vaccines to be Presented at AAPS in Washington, D.C.

October 11, 2018 9:35 AM

-Poster presentation showing retention of structural integrity and good immunogenicity of spray dried virosome-based vaccine stored at different temperatures and administered as a nasal powder -Poster presentation at AAPS - Washington, D.C., USA, Tuesday November 6th, 2018 EPALINGES, SWITZERLAND / ACCESSWIRE / October 11, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines...

Read more

Oncolix, Inc. Finalizes CycloSam(R) License Agreement For Osteosarcoma

October 10, 2018 4:45 PM

HOUSTON, TX / ACCESSWIRE / October 10, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the ''Company''), a biotechnology company focused on gynecological cancers, announced that the Company has finalized its license agreement from IGL Pharma, Inc., (''IGLP'') for a novel, clinical stage drug for the treatment of osteosarcoma. Other potential indications include bone metastases and bone marrow ablation. Highlights: License includes all uses for the...

Read more

Sandesara Promoted Sterling Biotech Limited to Settle Loans Outside IBC

October 8, 2018 3:37 AM

Sandesara Aims at Settling Loans Outside IBC by Promoting Sterling Biotech Limited MUMBAI, INDIA / ACCESSWIRE / October 8, 2018 / Through its representatives, Sterling Biotech is currently in discussions with the Committee of Creditors (CoC) to settle outstanding loan amounts. On June 11, 2018, the company was admitted for insolvency proceedings under the Corporate Insolvency Resolution Process (CIRP). The CoC'S legal representative has stated...

Read more

Pressure BioSciences Accelerates Development of Novel Ultra Shear Technology Platform to Pursue Commercialization into Major New Markets

October 3, 2018 9:25 AM

Company's Commitment Includes Significant Buildout of Manufacturing Space, Accelerated Instrument & Applications Development, Staff Additions, New IP Development, and Expanded Partnership Negotiations SOUTH EASTON, MA / ACCESSWIRE / October 3, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology...

Read more

Dyadic International to Present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX(R) Virtual Investor Conference

October 1, 2018 10:00 AM

JUPITER, FL / ACCESSWIRE / October 1, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it will present Thursday October 4, 2018 at 2:30 p.m. at the OTCQX® Virtual Investor Conference...

Read more

Oncolix, Inc. Signs Letter of Intent to Enter into a License Agreement to Treat Osteosarcoma

September 25, 2018 7:52 AM

HOUSTON, TX / ACCESSWIRE / September 25, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has entered into a non-binding letter of intent for an exclusive worldwide license agreement from IGL Pharma, Inc., ("IGLP") for a novel drug for the potential treatment of osteosarcoma, bone metastases and bone marrow ablation.Highlights: Proposal includes all...

Read more

Pressure BioSciences' Ultra High Pressure Instruments, Processing Methods, and Platform Technologies Prominently Featured at Leading Food Science Meeting

September 20, 2018 9:15 AM

SOUTH EASTON, MA / ACCESSWIRE / September 20, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' or the ''Company''), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that its ultra high pressure product line of instruments, methods, and technology platforms was prominently featured at the recent...

Read more

ReShape Lifesciences Announces Pricing of Public Offering

September 18, 2018 6:00 AM

SAN CLEMENTE, CA / ACCESSWIRE / September 18, 2018 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced public offering of 11,688,890 shares of its common stock and warrants to purchase up to 5,844,445 shares of its common stock, at a public offering price of $0.045 per share and associated warrant. The...

Read more

Pressure BioSciences Announces Commercial Release of the HUB880 Explorer

September 13, 2018 9:30 AM

Ultra High-Pressure Instrument Expected to Enhance the Science and Commercial Applications of High Pressure Processing Studies for Food Quality and Safety; Results Expected to Guide Development of the Company's Ultra Shear Technology Platform SOUTH EASTON, MA / ACCESSWIRE / September 13, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments,...

Read more

Pressure BioSciences Awarded Key U.S. Patent for Novel High-Pressure Flow-Through Microfluidic Sample Preparation Device

August 30, 2018 8:00 AM

Invention Opens Path for Integration of Automated ''Hands-Free'' Sample Prep Workflows Utilizing Company's Patented High-Pressure Platform Technologies SOUTH EASTON, MA / ACCESSWIRE / August 30, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' or the ''Company''), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences industry, today...

Read more

Molecular Partners Reports Key Financials for H1 18 and Corporate Highlights for the Second Quarter 2018: Promising MP0250 Clinical Data in Oncology and Positive Abicipar Phase 3 Efficacy Data Presented

August 30, 2018 1:00 AM

Promising initial data from MP0250 combination with bortezomib (Velcade®) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer supported by AstraZeneca with free drug supply. Immuno-oncology: ...

Read more